Navigation Links
Novavax Announces Early Retirement of $17 Million of Convertible Debt
Date:4/29/2009

Transaction removes significant financial obligation and improves balance sheet

ROCKVILLE, Md., April 29 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX), a leader in the development of novel vaccines, today announced that it has reached an early payoff agreement with holders of $17 million of the total $22 million in outstanding convertible notes. These convertible notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the early retirement, the Company will pay 70% of the principal plus accrued and unpaid interest in cash and will issue shares of its common stock for the remaining 30% of the principal by dividing that principal amount by $2.50 for a total payment of approximately $12 million in cash and 2,040,000 shares of common stock. The remaining $5 million in outstanding convertible notes will be due on July 15, 2009 and can be paid in cash at maturity at the Company's option.

"The transaction announced today to retire $17 million of our outstanding convertible notes removes a significant financial overhang from the Company. We have taken the opportunity to repay a larger portion of this debt in cash than was initially anticipated based on our current resources and market conditions. Removal of this indebtedness will allow the Company to continue its primary focus on the core mission of developing important new vaccines that can make a significant impact on human health," stated Rahul Singhvi, President and Chief Executive Officer of Novavax, Inc.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
2. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
3. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
4. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
5. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
6. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
7. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
8. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
9. Novavax CMO to Present at Phacilitate Vaccine Forum Washington 2009
10. NOVAVAX and the University of Massachusetts Medical School Announce Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate
11. Novavax to Present Seasonal Influenza Data Results in an Investor Conference Call on December 11, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... May 26, 2016 Despite the volatility ... in this space. Today,s pre-market research on ActiveWallSt.com directs the ... Inc. (NASDAQ: RDUS ), Cerus Corp. (NASDAQ: ... ), and Five Prime Therapeutics Inc. (NASDAQ: FPRX ... at: http://www.activewallst.com/ On Wednesday, ...
(Date:5/25/2016)... ... May 25, 2016 , ... Thailand’s Board of ... 2016 in San Francisco. Located at booth number 7301, representatives from the Thai ... and discuss the Thai biotechnology and life sciences sector. , Deputy Secretary ...
(Date:5/25/2016)... ... 2016 , ... WEDI, the nation’s leading authority on the use of health ... has been named by the WEDI Board of Directors as WEDI’s president and CEO. ... with more than 35 years of experience in healthcare, association management and organizational leadership, ...
(Date:5/24/2016)... ... , ... Last week, Callan Capital, an integrated wealth management firm specializing in ... San Diego Life Science event at the Estancia La Jolla Resort and Spa. , ... speakers Dr. Rich Heyman, former CEO of Aragon and Seragon, and Faheem Hasnain, former ...
Breaking Biology Technology:
(Date:4/28/2016)... and BANGALORE, India , April ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... today announced a global partnership that will provide ... to use mobile banking and payment services.      ... a key innovation area for financial services, but it also ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
Breaking Biology News(10 mins):